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  The risk of transmission of Herpes Simplex Virus from infected mothers to 
newborns is highest in mothers with active, symptomatic lesions. With the proper primary care, 
this population can be treated prophylactically to greatly reduce the risk of transmission. These 
babies can then be monitored closely for any sequalae indicating the disease. However, if 
neonates do not have the known risk factor of a mother carrying HSV, certain signs and 
symptoms in the neonatal period can alert physicians to the possibility of a neonatal Herpes 
Simplex Virus infection and prompt empirical treatment. 
 Methods 
  A retrospective chart review was done using data from the electronic medical 
records of Eastern Health. Eligible subjects who met inclusion and exclusion criteria were 
identified, and data from eligible charts was extracted and analyzed to form a picture of which 
infants were being treated for NHSV infection. 
 Results 
  Due to the small number of eligible subjects available from the time frame of the 
study, statistical analysis was limited. The mean age of the eligible population (neonates aged 0 
to 28 days) was 14 days old. The majority of these presented with fever. Three out of 17 
patients were treated presumptively with acyclovir, 2 of whom had presented with fever and 1 




  Unfortunately, due to the low number of eligible subjects, interpretation 
regarding which combination of symptoms and other characteristics lead to treatment with 
acyclovir cannot be completed.  A future direction in which to take this research question could 





Neonatal Herpes Simplex Virus infections occur when neonates become infected by 
Herpes Simplex virus. Although the overall incidence of Neonatal Herpes Simplex Virus (NHSV) 
infections is low, infections can have a high rate of morbidity and even mortality if it is not 
recognized. The low incidence of these infections is due, in part, to the fact that, if mothers 
have been symptomatic in the past, their condition will be known during pregnancy and the 
appropriate preventative measures can be taken (1).   
Common presentations of NHSV infections can be divided into 3 categories; 
mucocutaneous symptoms, central nervous system (CNS) symptoms and septic symptoms. 
Mucocutaneous symptoms include skin and oral lesions or rashes, CNS symptoms often present 
as seizure and septic symptoms as fever (1). These symptoms are non-specific to NHSV 
infections and may easily be attributed to another illness. The most specific of these symptoms 
that would lead a physician to think of NHSV infection are mucocutaneous lesions. If not 
recognized and treated, the sequalae of these symptoms can be devastating—when the 
nervous system is affected, encephalitis may lead to developmental delay and death (1).  
Using a retrospective chart review, this research project looks at which combination of 
these common symptoms and other features prompt treatment of neonates (infants between 
the ages of 0 and 28 days) with acyclovir in the Emergency Department (ED) setting, to answer 
the question: What are the predictors of acyclovir use in treating neonates presenting to the 
ED? 
As mucocutaneous lesions are more specific to the diagnosis of NHSV infection 
compared to fever or seizures (2), and therefore the presence of these characteristic lesions 
would prompt clinicians to consider the possibility of NHSV infection more readily, neonates 
with the presence of mucocutaneous lesions were not included in the study. 
 
Methods 
In order to address this question, a retrospective chart review was completed during the 
period of January 2018 through May 2018. The population used included infants aged 0 to 28 
days that had presented to the Janeway Emergency Department with a fever or first episode 
seizure over a three year period (April 1st, 2014 to March 31st 2017). The Janeway is the only 
pediatric ED in Newfoundland and Labrador. 
 A list of patients less than 28 days old who had presented to the Janeway ED, and had 
been successfully seen by a physician (ie: did not leave before being seen), with symptoms of 
fever or seizure, along with their Health Care Numbers, was obtained from Eastern Health 
Medical Records. The electronic medical record shows a scanned version of the physician notes 
from the ED visit, as well as any testing, procedures or treatments they received. This list was 
screened using a set of Inclusion and Exclusion criteria (see appendix) to determine eligibility 
for the review. Eligibility included factors such as presenting symptom (fever or first episode 
seizure), age and admission as an inpatient. Patients were excluded if they were known to have 
had interventions for HSV infections in the past.  Once determined eligible, each case was 
issued a study ID and the data was extracted from the Eastern Health Electronic Medical Record 
using a paper data extraction form (see appendix).  
 Data collected from patient charts included age, sex, weight, time of triage, presenting 
symptoms, investigations and results, treatment given and length of admission. 
This variety of information allows for a complete picture to compare those patients who 
received treatment with acyclovir with those who did not. With it, a comparison of variables 
such as age, sex, weight, type of antibiotics received and time they were given, can be made. 
The data analysis for the study was completed using the program SPSS. This program is 
available for use of medical students at Memorial University. The data was analyzed using 
descriptive statistics, including mean, median, mode and standard deviation. 
 
Results 
Measures of central tendency, as well as standard deviation for continuous variables 
describing baseline characteristics, such as age in days and weight in kg and the frequency 






Table 1: Baseline characteristics (age, sex, weight and presenting symptom) of eligible patients 
 Age of patient in 
days 
Sex of patient 
Male  |Female 
Weight of 
patient in kg 
Presenting 
Symptom 
Fever   |    Seizure 
N 17 9               8 17 13                    4 
Mean 14.1  3.5  
Median 12.0  3.6  
Mode 8.0  4.0  
Standard 
Deviation 
7.8  0.5  
 
 
Table 2: Frequency values of outcomes 
Variable Frequency Percent 
Type of antibiotic given   
      Ampicillin 2 11.8 
     Ampicillin & Cefotaxime   1 5.9 
     Ampicillin & Gentamicin 6 35.3 
     Cefotaxime &Gentamicin 6 35.3 
     None 2 11.8 
Time to Antibiotics in hours   
    None given 2 11.8 
   < .40 1 5.9 
    0.40 - 2.0 2 11.8 
    2.0 - 2.5 1 5.9 
    2.5 - 3.0 2 11.8 
    3.0 - 3.2 1 5.9 
    3.4 - 3.5 1 5.9 
    3.5 - 4.0 3 17.6 
    4.0 - 5.0 1 5.9 
    5.0 - 9.0 3 17.6 
Lumbar Puncture Given   
     Yes 9 52.9 
     No 8 47.1 
Acyclovir Given   
    No 14 82.4 
    Yes 3 17.6 
 
 
 Out of the 17 cases that were eligible to be included in the study, three of those patients 
received treatment with acyclovir. These cases are outlined below: 
 Case 1 
  Age: 8 days 
  Weight: 4.0 kg 
  Sex: Male 
  Presenting Symptom: Fever 
  Investigations: Complete blood count  
Lumbar puncture: small amount of white blood cells, many red 
blood cells, no bacteria visible under microscopy, no growth on 
culture  
PCR: no HSV DNA detected  
Urine studies: E. coli growth on culture  
Chest x-ray: clear  
Blood culture: no growth 
Stool culture: no growth 
  Acyclovir: Administered at 07:00 (5.5 hours from triage). Dose of 80 mg 
  Antibiotics: Ampicillin (dose of 200 mg) administered 4 hours after triage. 
Gentamycin (dose of 16 mg) administered 4.5 hours after triage. 
 Case 2 
  Age: 6 days 
  Weight: 3.5 kg 
  Sex: Female 
  Presenting Symptom: Seizure 
  Investigations: Complete blood count  
Lumbar puncture: Occasional white blood cell, no bacteria seen 
under microscopy, Streptococcus viridans grown on culture (likely 
due to contamination) 
PCR: no HSV DNA detected 
Urine studies: E. coli grown on culture 
Cranial ultrasound: normal 
Blood culture: no growth 
  Acyclovir: Dose of 70 mg administered at 08:00 (15 hours from triage) 
  Antibiotics: Gentamycin (dose of 14 mg) administered 10 hours from triage, 
Ampicillin (dose of 175) administered 9 hours from triage 
 
 Case 3 
  Age: 3 days 
  Weight: 3.02 kg 
  Sex: Male 
  Presenting Symptom: Fever 
  Investigations: Complete blood count 
Lumbar puncture: Occasional white blood cells, no bacteria seen 
under microscopy, no growth on culture 
PCR: No HSV DNA detected 
Urine studies: Coagulase-negative staphylococci grown on culture 
(suspected contamination) 
Chest x-ray: clear  
Blood culture: no growth 
  Acyclovir: Dose of 60 mg administered at 07:20 (15 hours from triage) 
  Antibiotics: Ampicillin (dose of 300 mg) administered at 12 hours from triage, 
Gentamycin (dose of 14 mg) administered at 7.5 hours from triage. 
 
Interpretation 
The majority of neonates that presented to the ED during the study period presented 
with fever (n=13), while a fewer number presented with first episode seizure (n=4). This is to be 
expected, as fever in the neonatal population is much more common than seizure-like activity. 
The symptoms of fever and seizure were mutually exclusive in these cases: there were no 
patients that presented with both symptoms. The mean age of patient presentation was 14 
days, while the male to female ratio of the patients was roughly equal.  
The most commonly given combinations of antibiotics were ampicillin and gentamicin 
(n=6) and cefotaxime and gentamicin (n=6). Two of the eligible patients did not receive 
antibiotics. The mean time to antibiotic administration was 3.7 hours from triage. Only one of 
the patients treated with antibiotics received them within an hour of triage.  
52.9 % of the presenting neonates received a lumbar puncture while 47.1 % did not. Of 
the 9 neonates that received a lumbar puncture, 3 of them were treated with acyclovir. Two of 
those patients presented with fever, while the other presented with seizure. 
All patients that received treatment with acyclovir were also treated with Ampicillin and 
Gentamycin; however, the timeliness of antibiotic administration varied. It was determined 
from the results of the PCR of the cerebrospinal fluid, that out of the three patients that were 
treated prophylactically with acyclovir, none were infected with Herpes Simplex Virus. 
From the sample of 17 eligible patients, three patients were treated with acyclovir. Out 
of those three patients, two presented with fever while the other presented with seizure. All of 
the patients treated with acyclovir were less than 9 days old. Before administration of acyclovir, 
all patients were treated with both Ampicillin and Gentamycin. No HSV DNA was detected by 
PCR in any of the patients that received acyclovir. 
It is interesting that in the study sample, the mean time to administration of antibiotics 
was 3.7 hours. Research within the field shows that it is ideal to treat febrile neonates within 
the first hour of presentation (3). Only one patient from this population received antibiotics 
within that ideal time frame. It is also interesting to note that only approximately half of 
patients received a lumbar puncture, where guidelines suggest all febrile neonates to be 
worked up with a lumbar puncture, unless unstable (4). 
This study was conducted using a population of infants aged 0 to 28 days who presented 
to the Janeway ED in a 3 year period. Of this population, 17 patients were deemed eligible 
based on the Inclusion and Exclusion criteria. Seventeen patients is a relatively small sample 
size for a chart review comprised of 3 years of ER visits, and suggests to the investigators that 
all eligible patients were not identified. This small sample size is a major limit to the study. With 
a larger sample size, more meaningful comparisons could have been made. As only 3 infants in 
the population were ultimately treated with acyclovir, no trends can be drawn from this data. 
This small sample size also affects the statistics available to analyze the data. 
Additionally, it is limited by the time frame allowed for this project within the medical school 
curriculum. Given more time, a larger number of charts could be reviewed to obtain a larger 
sample size 
In conclusion, the data obtained for this project was insufficient to answer the research 
question. If this research were to be taken further, it would be feasible to use the data from 5 
years of ED visits, and perhaps use other methods to ensure identification of all eligible 
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Recognizing and treating Neonatal Herpes Simplex Virus in Neonates Presenting to a Pediatric 
Emergency Department: Predictors of Acyclovir Use 
Inclusion/Exclusion Criteria 
Screening ID: ___________________ 
Inclusion Criteria: 
 Age <28 days: _______  Y ________  N 
 Presented to the Janeway Emergency Department and seen by an Emergency Department 
physician: _______     Y   _________ N 
Confirmed fever or unexplained seizures: _______   Y   _________  N 
Admitted to the Janeway as an inpatient: ________ Y   __________ N 
Exclusion Criteria: 
Neonatal Intensive Care Unit interventions for HSV prior to Emergency Department presentations: 
________ Y  _________ N  
 
 
Eligible _______ Y ________ N 











Data Extraction Form 
Study Enrolment ID: __________________ 
Age (in days): __________ 
Sex: ________ Male   __________ Female 
Weight (kg): _______________ 
Triage Code: __________________ Time of Triage (24 hr clock): ______________ 
Presenting Symptoms: __________ Fever  ____________ Seizure   
Onset of Symptoms (hours): _______________________ or > 24hrs: ______________ 
Investigations and Results: 
 Complete Blood Count: __________Y  _____________ N 
  Results: WBC (109 /L) ______             Neutrophils (109 /L) ________ 
  Lymphocytes (109 /L) _______    Monocytes (109 /L) ________ 
 Lumbar Puncture: ______________ Y ______________ N 
Done before antibiotic administration: _________ Y ___________ N   
Results: WBC (109 /L) ______ RBC (109 /L) ________ 
Neutrophils (109 /L) _______ Lymphocytes (109 /L) _______ 
Monocytes (10 9 /L) ________ Other (10 9 /L) ___________ 
Glucose (mmol/L)________ Protein (g/L)___________ 
Gram stain:_______________________________________________________ 
Culture: _________________________________________________________ 
  PCR: ______________ Y  _________________ N 
  Results: ____________________________________________________ 
 Urine Studies: _____________ Y ________________ N 
  Results: ___________________________________________________ 
 Imaging: ______________Y  ________________ N 
  Type: _____________________________ 
  Results: ___________________________________________________ 
 Blood Culture: _______________Y  ______________ N 
  Results: ___________________________________________________ 
 Nasopharyngeal Swab: _____________ Y    _________________ N 
  Results: ___________________________________________________ 
 Other: __________________________________________________________ 
Treatment: 
 Acyclovir Administered: __________Y    ____________ N 
  Dose (in mg): _________________ 
Time of first dose (minutes from triage): ________________ 
Location of First Dose: __________ ED _________ Ward _________ PICU/NICU 
 Antibiotics Administered: ________ Y  ________N 
  Antibiotic 1: _______________ 
   Dose (in mg): _______________ 
   Time of first dose (minutes from triage): ________________ 
   Location of First Dose: ______ ED _________ Ward ________ PICU/NICU 
  Antibiotic 2: _______________ 
   Dose (in mg): _______________ 
   Time of first dose (minutes from triage): ________________ 
   Location of First Dose: ______ ED _________ Ward ________ PICU/NICU 
 
 Length of Admission (days): _____________________________________ 
 
 
